AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02675452
Age 18 - 85
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
AMG 176 is a medicine that has been tested on people who have a type of cancer called multiple myeloma or acute myeloid leukemia. The test showed that a certain amount of the medicine is safe and can be tolerated by the patients.
AMG 176 is a medicine that has been tested on people who have a type of cancer called multiple myeloma or acute myeloid leukemia. The test showed that a certain amount of the medicine is safe and can be tolerated by the patients.
Third Opinion AI Generated Synopsis
Trial Summary
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
